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Purpose: To investigate whether associations with the nitric oxide synthase gene (NOS3) variants and risk of primary
open-angle glaucoma (POAG) depend on female reproductive factors.
Methods: Two functional and two tagging single nucleotide polymorphisms (SNPs; T-786C: rs2070744, Glu298Asp:
rs1799983, rs7830, and rs3918188) were evaluated in a nested case-control study from the Nurses’ Health Study (women
followed 1980 – 2002). Participants were aged ≥40 years and Caucasian, who were followed biennially with update
information on reproductive factors. We included 374 Nurses’ Health Study (NHS) cases and 1,085 controls, matched on
age and eye exam at the matched cases’ diagnosis dates. Relative risks (RRs) were estimated using multivariable
conditional logistic regression.
Results: Among women with age at menarche <13 years, compared with the CC homozygotes of the rs3918188 tagging
SNP, the wild-type AA homozygotes were at significantly reduced risk of POAG (RR=0.31, 95% CI=0.16, 0.59); however,
for women with age at menarche ≥13 years, the SNP was not associated with POAG (p-interaction=0.0007). Among
parous women with 3+ children, carriers of the minor variant (T) allele of the functional Glu298Asp SNP were at increased
risk, while among parous women with 1–2 children, they were not (p-interaction=0.003). No significant interactions
between NOS3 SNPs and oral contraceptive use in POAG were detected.
Conclusions: These data provide further support for the notion that  NOS3 genotype - female reproductive health
interactions are important in POAG pathogenesis.
Nitric  oxide  synthase  3  (NOS3)  is  an  enzyme  that
catalyzes  the  production  of  nitric  oxide  (NO),  which
modulates the tone of luminal structures with adjacent smooth
muscle tissue [1]. NOS3 may play a role in the etiology of
glaucoma; it is found in the human outflow pathway [2] and
the vasculature supplying retinal ganglion cells [3], which
may affect the regulation of intraocular pressure (IOP) and
blood flow to the optic nerve, respectively.
Dysfunction in the ocular vascular endothelium and in the
trabecular meshwork cells could lead to primary open angle
glaucoma  (POAG).  Feke  and  Pasquale  [4]  documented
unstable retinal blood flow after physiologic alterations in
ocular perfusion pressure, which implicates dysfunction in
NO-mediated responses [5-7]. NO also influences trabecular
meshwork cell volume and outflow facility [8-10] that in turn
influences IOP, an established POAG risk factor.
Reproductive hormones such as estrogen may play a role
in modulating IOP and the risk of POAG in women [11-19].
One  mechanism  for  this  protective  effect  might  be  that
estrogen upregulates NOS3, thereby enhancing the release of
nitric oxide [20-23] to regulate blood flow to the optic nerve
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and the outflow facility. Previously, we observed that early
menopause was associated with an increased risk of POAG
and current use of estrogen with progestin was associated with
a reduced risk of high tension POAG [24]. Also, we observed
associations with nitric oxide synthase gene (NOS3) variants
that were significantly stronger in women than in men and
evidence of stronger associations with NOS3 variants among
current users of postmenopausal hormones (PMH) compared
to non-current users in relation to high-tension POAG [25].
In this study, we evaluated whether the associations with
NOS3 variants and the risk of POAG depended on the status
of  reproductive  factors  of  age  at  menarche,  parity,  oral
contraceptive use. We used data from a large case-control
study nested within the Nurses’ Health Study (NHS) where
for cases, the exposure information was collected before any
diagnoses of POAG.
METHODS
Study  population:  The  NHS  was  initiated  in  1976,  when
121,700  female  US  registered  nurses  (aged  30–55  years)
returned a questionnaire on health-related information [26].
Participants have been followed with biennial questionnaires
to update information on lifestyle factors and newly diagnosed
illnesses, such as glaucoma [27]. Follow-up rates were high
(>95% of the total possible person-time through 2002). The
Human  Research  Committees  of  Brigham  &  Women’s
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this study.
Blood  and  cheek  sample  collection:  In  1989–1990,  blood
samples were collected from 32,826 (27%) women. In 2001–
2004, among 29,684 women who did not provide a blood
sample, buccal cell samples were collected.
Blood samples were collected using sodium heparin as
the anticoagulant. Samples were mailed back within 26 h of
blood draw, immediately centrifuged, aliquoted into buffy
coat components, red blood cells, and plasma, and stored in
liquid nitrogen freezers for later retrieval. Buccal cell samples
were  collected  using  a  single  “swish-and-spit”  procedure
(women were provided a small bottle of mouthwash and a
small  cup  with  a  cap  seal  and  were  asked  to  swish  the
mouthwash and then spit into the cup, which was returned by
mail). Within a week of receipt, samples were processed
and DNA was extracted.
Case and control ascertainment: We first identified POAG
cases  with  the  biennial  questionnaires,  where  we  asked
whether participants received an eye exam with a diagnosis
of “glaucoma.” For participants self-reporting glaucoma, we
sought  permission  to  retrieve  the  medical  records.  We
contacted the diagnosing eye care provider for all prior visual
field  (VF)  tests  and  for  the  completion  of  a  glaucoma
questionnaire; this questionnaire included items for maximal
IOP,  the  status  of  the  filtration  apparatus,  optic  nerve
structural information, prior ophthalmic surgery, and any VF
loss.  Relevant  medical  records  were  accepted  in  lieu  of
questionnaires.  All  confirmatory  information  from
questionnaires/medical records and VFs were evaluated in a
standardized manner by a glaucoma specialist (L.R.P.). We
previously  demonstrated  our  case  definition  is  valid  by
showingappropriatepositiveDssociations Zith DIDPLO\
history of glaucoma and with African heritage [2].
We included as cases only participants determined to
have “definite” or “probable” POAG. For definite POAG
cases (70% of case), slit lamp biomicroscopy showed no sign
of  pigment  dispersion  syndrome,  uveitis,  exfoliation
syndrome,  trauma,  or  rubeosis  in  either  eye;  gonioscopy
demonstrated that the angles were open in both eye; and ≥2
reliable VFs showing reproducible defects consistent with
glaucoma had to be available. For probable POAG cases, the
same slit lamp exam and VF criteria were also required, but
documentation of pupil dilation without subsequent adverse
events was accepted if gonioscopy was not performed. For
VFs,  there  was  no  requirement  for  the  type  of  perimetry
performed; however, in 95% of cases, full static threshold
testing was completed, and in <1% of cases, kinetic VFs were
used. For static threshold or suprathreshold tests, we regarded
the VF reliable if the fixation loss rate was ≤33%, the false
positive rate was ≤20% and the false negative rate was ≤20%.
For kinetic VFs, we considered the field reliable unless the
examiner noted otherwise.
We included 374 cases and 1,085 control subjects who
were at least 40 years in age and Caucasian. The controls were
matched on sample type (blood or cheek cell), year of birth,
ethnicity (Latino or not), and they were required to have had
an eye exam in the same period as when the matched case was
diagnosed.  Approximately  three  controls  per  case  were
matched to each case, using incidence density sampling.
Genotyping: We genotyped two functional single nucleotide
polymorphisms  (SNPs)  (T −786C:  rs2070744  and
Glu298Asp: rs1799983) and two tagging SNPs (rs3918188,
and rs7830). The tagging SNPs corresponded to the NOS3
linkage disequilibrium (LD) blocks, and were selected using
Haploview  (version  4.1)  according  to  the  HapMap  data
(release  22)  from  the  Utah  residents  with  Northern  and
Western European ancestry (CEU) population [],  withWhe
minimum  minor  allele  frequency  set  to  0.01.  The  two
functional SNPs and the two tagging SNPs (rs3918188 and
rs7830) captured the majority (88%) of alleles at r2 greater
than 0.8 across the whole gene, including the 5′- and 3′-
untranslated regions.
For DNA extraction, 50 μl of buffy coat or 20 μl of cheek
cells were diluted with 150 μl of PBS and processed via the
QIAmp (QIAGEN Inc., Chatsworth, CA), 96 spin blood kit
protocol.  A  quantitative  PCR  approach  (TaqMan  assay;
Applied  Biosystems,  Inc.;  Foster  City,  CA)  was  used  for
genotyping, according to the manufacturer’s instructions. The
RT–PCR amplification of whole genome amplified DNA was
performed in 96 well plates with a sequence detection system
(ABI  Prism©  7000  Sequence  Detection  System;  Applied
Biosystems Inc., Foster City, CA). The thermal cycler (model
2720; Applied Biosystems Inc., Foster City, CA) was set at
the following parameters: 50 °C for 2 min, 95 °C for 10 min,
92 °C for 15 s, and 58 °C for 1 min for a total of 60 cycles.
The genotyping success rate was over 90%. Plates that passed
quality  control  measures  (including  Hardy–Weinberg
equilibrium tests) were included, and in 5% of samples that
underwent repeat genotyping, there was >95% concordance
on genotyping calls.
Assessment of reproductive factors:
Age at menarche and age at menopause—From 1976,
participants were asked about the age at menarche and when
menstrual periods ceased permanently. Additional questions
were  asked  of  menopausal  women,  including  type  of
menopause (natural, surgical, or radiation) and, if surgical
menopause,  the  number  of  ovaries  removed.  Menopausal
status was updated biennially.
Oral contraceptive (OC) use—Current and past OC use
was asked at 1976 and updated biennially until 1984, at which
point no women reported current use. Women were also asked
to report the time periods for which they used OCs and reasons
for stopping.
Parity—Parity, which was defined as pregnancy lasting
at least 6 months, was assessed in 1976 and biennially updated
through 1984 and updated again in 1996.
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to estimate relative risks (RRs) and 95% confidence intervals
(CIs),  adjusting  for  potential  confounders.  We  used  SAS
(version 9.1.3; SAS, Cary, NC) for analyses, and a value of
p<0.05 was considered statistically significant. To address the
multiple testing issue, in secondary analyses, we calculated
adjusted  p-values  using  an  optimized  false  discovery  rate
approach [3].
Information on exposures and potential confounders was
obtained from the biennial questionnaires and was updated
through the questionnaire immediately before the diagnosis
date of the index case. Potential confounders were family
history of glaucoma, body mass index (<22, 22–23.9, 24–
25.9,  26–27.9,  28–29.9,  ≥30  kg/m2),  physical  activity
(quartiles of activity intensity/day), self reported history (yes/
no) of diabetes, and cumulatively updated caffeine intake (0–
149,  150–299,  300–449,  450–600,  ≥600  g/day),  age  at
menopause (20–44, 45–50, 50–54, 54+ years), PMH status
(never, past, current user), age at menarche (linear years),
parity (linear number of children), and oral contraceptive use
(never, ever).
In secondary analyses, we separately analyzed the risk of
“high-tension”  POAG,  defined  as  those  with  maximum
IOP≥22 mmHg before VF loss (67.5% of all POAG cases)
and “normal-tension” POAG, defined as those with maximum
IOP<22 mmHg before VF loss.
To  evaluate  effect  modification,  we  tested  the
significance of the estimates of the interaction terms from the
multivariable conditional logistic regression models, using
Wald tests, where the term was constructed as a product of the
SNP variables that were coded as 0, 1, 2, and the reproductive
factor of interest.
RESULTS
The characteristics of POAG cases and their matched controls
as of the index case’s date of diagnosis were similar (Table
1).  Cases  had  a  higher  frequency  of  a  family  history  of
glaucoma and self-reported diagnosis of diabetes; however,
the cases were somewhat less likely to smoke, drink alcohol
or be obese. Among women, the cases were less likely to be
current PMH users.
Summary of main effects of NOS3 SNPs: The main effects
of the NOS3 polymorphisms in relation to POAG have been
previously reported [25]. Briefly, we observed that none of
the variants were associated with overall POAG except for
rs3918188,  where  the  variant  was  significantly  (p=0.04)
inversely  associated  with  overall  POAG  only  among  the
women (Table 2). In secondary analyses, we found that the
T-786C  polymorphism  was  associated  with  high-tension
POAG only among the women (RR=1.80 (95% 1.14, 2.85; p-
trend  with  increasing  variant  allele=0.02),  as  was  the
polymorphism in the tagging SNP rs3918188 (RR=0.48 (95%
CI 0.28, 0.82); p-trend with increasing variant allele=0.0008).
In  relation  to  normal-tension  glaucoma,  for  the  T-786C
polymorphism, the “pooled” RR (meta-analyzed RR from
NHS and HPFS results) for the CC homozygote was 0.44
(95% CI, 0.22, 0.87) and the p for trend was 0.03.
Effect modification with age at menarche: We observed
a significant interaction between NOS3 SNP rs3918188 and
TABLE 1. CHARACTERISTICS OF CASES OF PRIMARY OPEN-ANGLE GLAUCOMA AND THEIR MATCHED CONTROLS AS OF DIAGNOSIS
DATE.
Characteristic Cases Controls
N 374 1085
Age (mean, yr) 64.1 64.0
Family history of glaucoma (%) 35.6 12.2
Diabetes (%) 7.8 5.1
Obesity (Body mass index ≥30 kg/m2, %) 14.0 15.1
Hypertension (%) 37.4 39.0
30+ pack years of smoking (%) 18.2 18.9
Caffeine (mean, mg/day) 313.8 308.0
Alcohol intake (mean, g/day) 6.1 6.2
Number of reported eye exams† 3.1 3.2
Age at menopause (mean, years) 50.1 50.6
Current postmenopausal hormone use (%) 39.8 42.7
Oral contraceptive use (%) 42.5 39.7
Age at menarche (mean, years) 12.6 12.7
Number of children among parous women (mean) 3.3 3.4
†Eye exams have been asked every two years, seven times from 1990- 2002; the number represents the number of eye exams
reported as of the period of the diagnosis date of the index case in matched case control sets.
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2547age  at  menarche  in  POAG.  Specifically,  the  inverse
association between the rs3918188 polymorphism and POAG
was more evident among those with age at menarche <13
years, after adjustment for age at menopause and other factors
(p for interaction=0.0007; significant after multiple testing
correction; Table 2). Among those with age at menarche <13
years, compared with the CC homozygotes of the rs3918188
tagging  SNP,  the  AA  homozygotes  were  at  significantly
reduced  risk  of  POAG  (RR=0.31,  95%  CI=0.16,  0.59);
however, among those with age at menarche ≥13 years, the
SNP was not associated with POAG. On the other hand, we
did not find a significant interaction between the functional
NOS3 Glu298Asp SNP and age at menarche. Among women
with age at menarche <13 years, the adverse association with
the Glu298Asp polymorphism was more apparent (RR for TT
homozygotes versus GG homozygotes=2.13, 95% CI=1.20,
3.77) than among those with older age at menarche. This
interaction was borderline significant (p=0.05), and was no
longer significant after multiple testing correction.
Effect  modification  with  parity:  Because  80%  of  our
participants  were  parous,  we  did  not  have  the  power  to
examine nulliparity; thus, we examined having 3 or more
children  versus  having  1–2  children  for  evaluating  effect
modification.  We  did  observe  a  significant  crossover
interaction between the Glu298Asp SNP and parity in POAG.
Using women with multiparity who were homozygous for the
common  Gl298Asp  NOS3  variant  (GG)  as  the  reference
group, both homozygosity for the minor Glu298Asp variant
(TT) among those with 3 or more children and homozygosity
for  the  common  variant  (GG)  among  women  with  1–2
children  were  adversely  related  to  POAG  (p=0.003;
significant after multiple testing correction; Table 2). On the
other hand, we did not find a significant interaction between
the rs3918188 SNP and parity in POAG. Among those with
3  or  more  children,  the  protective  association  with  the
rs3918188 SNP was more apparent (RR for AA homozygotes
versus  GG  homozygotes=0.56,  95%  CI=0.24,  1.33)  than
among those with 1 or 2 children, but this interaction was
borderline significant (p=0.04) and was no longer significant
after multiple testing correction.
Effect modification with oral contraceptives: We did not
observe any significant interactions between  the  four  NOS3 
SNPs  with  oral  contraceptive  use  (Table 2)  in relation to
Secondary analyses: None of the NOS3 SNP – female
reproductive health attribute showed significant interactions
in POAG cases with IOP≥22 mmHg at diagnosis or in POAG
cases with IOP≤21 mmHg at diagnosis.
DISCUSSION
In this nested case-control, we observed that the associations
with NOS3 SNPs in relation to POAG depended on age at
menarche and parity, where those associations were most
evident among those with greater estrogen exposure (age at
menarche <13 years and parity of 3 or more children versus
1–2  children).  Interactions  were  not  observed  with  oral
contraceptives in relation to POAG overall. Because this is
the first study to examine the interaction between NOS3 SNPS
and  female  reproductive  factors,  these  results  need  to  be
confirmed in other studies.
These findings should be interpreted in the context of
previous  cohort  studies  describing  the  relation  between
reproductive  factors  and  POAG  [24,25,31].  For  age  at
menarche, in the NHS, we previously found that menarche
>13 years was associated with increased risk of POAG with
IOP≤21 mmHg at diagnosis [31], which was consistent with
the finding from the Blue Mountain Eye Study that reported
that later age at menarche was associated with an increased
risk of OAG [32].  These d     ata suggest that increased lifetime
estrogen exposure during the reproductive years, as reflected
in earlier menarche, is associated with POAG. Among the
NOS3 SNPs, the functional consequences of the rs3918188
tagging SNP are unknown; however, we previously found that
the minor allele (A) was associated with a reduced risk of
POAG in women (p-trend=0.04) but not men (p-trend=0.58).
We  observed  a  significant  interaction  between  the  minor
allelic  variant  of  the  rs3918188  tagging  SNP  and  age  at
menarche in POAG: women with homozygosity for the minor
allele and age at menarche <13 years had a 69% reduction in
POAG risk compared to those with homozygosity for the
wild-type allele and older age at menarche. Biologically, this
is plausible as increased age at menarche may be related to
reduced  NOS3  activity  [33],  which may also  reduce
endothelial cell relaxation in the trabecular meshwork cells
and in the vascular endothelium that supply retinal ganglion
cells.  In  addition,  we  previously  observed  significant
interactions between this same SNP and current PMH use in
POAG with IOP>21 mmHg at diagnosis: postmenopausal
women with homozygosity for the minor allele and current
users of PMH had a 67% reduced risk of high tension POAG.
We  also  observed  that  the  association  between  the
functional  Glu298Asp  SNP  and  POAG  was  significantly
modified by parity. For parity, in the NHS, we reported a null
association with POAG [31], although the Blue Mountain Eye
Study observed that increasing parity was associated with an
increased risk of OAG [32]. For the functional  Glu298Asp
SNP, which is known to reduce intercellular nitric oxide levels
[34,35], we previously did not find an association with POAG
in  women  or  in  men,  nor  any  interactions  with  age  at
menopause or PMH use. Here, we observed a “cross-over”
interaction where the wild type genotype was associated with
increased POAG risk for women with parity <3, while the
dysfunctional genotype was associated with increased risk for
women  with  parity  3+.  Multiparity  is  known  to  produce
endothelial  dysfunction  through  reduced  nitric  oxide
bioavailability  [36],  thus,  it  is  plausible   that  multiparity-
induced  endothelial  dysfunction  may  be  exacerbated  in
homozygotes of the dysfunctional NOS3 variant. The adverse
Molecular Vision 2011; 17:2544-2551 <http://www.molvis.org/molvis/v17/a275> © 2011 Molecular Vision
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POAG.association with the common SNP among those with lower
parity is relative to women of the same genotype who had
more children. Perhaps in the latter instance lower circulating
estrogen  milieu  in  women  with  low  parity  may  be  more
important than multiparity-induced endothelial dysfunction in
dictating POAG risk. We have previously reported a “cross-
over” type interaction for the functional T-786C SNP and
hypertension and POAG [3]. ItUemainsWoEe Getermined
whether crossover interactions have real pathophysiological
significance.
The  associations  between  the  NOS3  SNPs  and
reproductive factors that reflect exposure to estrogen, which
potently modulates NOS3 activity, provides further support
for the important role of endothelial cell dysfunction in POAG
etiology. Such dysfunction in the trabecular meshwork and
ocular vascular endothelium may lead to increased IOP and
retinal ganglion cell vulnerability, resulting in glaucomatous
visual loss. Recent emerging data from animal models, studies
of  POAG  genetics  and  clinical  trials  of  agents  related  to
vascular tone also support this hypothesis. In a mouse model,
there is evidence that knocking out soluble guanylate cyclase,
the downstream mediator of nitric oxide, produces modest
increases in IOP and considerable loss of retinal ganglion cells
and nerve fiber layer dropout [3].,n an,celandic genome-
wide  association  study  of  POAG,  gene  variants  in  the
intergenic region between caveolin 1 and caveolin 2, which
code for caveolins that reside near NOS3 in endothelial cell
membranes  and  serve  to  mediate  endothelial  tone  were
associated with POAG []. A randomized clinical trial found
that topical brimonidine, an alpha 2 agonist with vasomotor
activity at the level of the retinal vascular endothelial cells,
was superior to timolol, in preserving vision in the normal
tension variant of POAG [4-4].2ther  studiesRf statins,
which also improve endothelial cell function, have found that
they may favorably alter the course of POAG [4,4]. Thus,
our data, in combination with emerging data from laboratory
as well as human studies, coherently implicate endothelial cell
dysfunction in POAG pathogenesis.
There  are  limitations  to  this  work  that  should  be
considered. First, our glaucoma definition was based on self-
report  with  confirmation  with  medical  records  and  visual
fields. This definition has very high specificity, as we required
documentation of reproducible defect on at least 2 reliable
visual  field  tests  and  we  have  demonstrated  strong
associations with established risk factors, such as African-
American  heritage  and  family  history  [2].  GivenWhe
insidiousness of glaucoma, some controls might have had
undiagnosed glaucoma. However, it is unlikely to have had a
major influence on our results, as the prevalence of glaucoma
in adults over age 40 is 1.3% in Caucasians [4]. Furthermore,
our  controls  had  an  eye  exam  as  of  the  matched  cases’
diagnosis dates. In fact, the average number of eye exams
reported as of their selection as controls were three exams,
implying that manifest glaucoma, if present, would likely
have  been  detected.  Any  misclassifications  of  the  disease
would have biased the results toward the null. Third, our
participants were generally healthy Caucasians and thus we
are unable to make inferences to less healthy populations or
minorities. Finally, it is possible that our results may be due
to chance, despite the fact we showed statistical significance
after accounting for multiple comparisons. Therefore, these
findings should be interpreted with caution and confirmed in
future studies, particularly with different racial/ethnic groups.
In conclusion, the associations between NOS3 SNPs and
POAG depended on parity and age at menarche. Previously
we showed the associations between NOS3 SNPs and POAG
depended on PMH use. These data indicate that NOS3 gene
variants interact with sex hormone levels in ways to influence
the risk of POAG. In the future we hope to validate these
interactions in animal model systems.
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